The first patient has been dosed for Sangamo Therapeutics' Phase I/II trial to evaluate its genome-editing therapy candidate SB-FIX in patients with severe hemophilia B. The study will assess SB-FIX in 12 participants, who will be given a low, medium or high dose to establish its preliminary effectiveness, safety and tolerability.
Dosing initiated for hemophilia B genome-editing therapy candidate
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.